|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
CalciMedica
| CalciMedica 505 Coast Blvd S. Suite 209 La Jolla, CA 92037 | |
| | Phone: | (858) 952-5500 | Fax: | (858) 952-5490 | Year Established: | 2006 | Main Contact: | Michael Dunn, MBA, President & CEO | | Other Contacts: | Sudarshan Hebbar, MD, Senior VP, Clinical Development Kenneth A. Stauderman, Ph.D., Co-founder and VP, Research
| | Company Description | CalciMedica is dedicated to the discovery and development of novel small molecule drugs for the treatment of autoimmune and inflammatory diseases. A significant focus of the company's drug discovery strategy is based on the specific inhibition of calcium release-activated calcium (CRAC) channels, a key component of the Icrac pathway in immune cells. The Icrac calcium entry pathway is essential for the adaptive immune response, and has been validated as an important drug target in humans. CalciMedica has acquired exclusive rights to STIM1 and Orai1 that function together as gatekeepers of the Icrac pathway and were cited in Science among signaling breakthroughs of 2005 and 2006, respectively. CalciMedica was founded in 2006 and received its initial funding from SR One. | |
|
|
|
|
|